Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591006 · ClinicalTrials.gov registry record · Phase 3
Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT00591006 is a Phase 3 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT00591006, a Phase 3 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this research is to determine if patients who receive phenytoin (also commonly known as Dilantin) before taking corticosteroids will show less memory impairment and hypomanic symptoms (feelings of agitation, overexcitement or hyperactivity) than those receiving placebo (an inactive substance). This research also seeks to determine if patients taking phenytoin before corticosteroids show more activity in the area of the brain involved with memory than those receiving placebo. This research is being done because increased levels of cortisol (the body's natural corticosteroid) in the body are frequently associated with forgetfulness, and interventions that may prevent or reverse this effect are of great importance.
Interventions
- DRUG Placebo
- DRUG Hydrocortisone
- DRUG Phenytoin (brand name Dilantin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591006
The ClinicalTrials.gov registry entry for NCT00591006 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00591006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00591006 about?
NCT00591006 is a clinical study titled "Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes". The purpose of this research is to determine if patients who receive phenytoin (also commonly known as Dilantin) before taking corticosteroids will show less memory impairment and hypomanic symptoms (feelings of agitation, overexcitement or hyperactivity) than those receiving placebo (an inactive su...
What is the current status of trial NCT00591006?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00591006?
The interventions under investigation include: Placebo (DRUG), Hydrocortisone (DRUG), Phenytoin (brand name Dilantin) (DRUG).
Who is sponsoring clinical trial NCT00591006?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.